Skip to content

Study · Randomized controlled trial · n = 18 · 2001

3 results

Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy.

Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme1 May 2001Cited by 59 (Europe PMC)

PMID11440277 (opens in a new tab)DOI10.1055/s-2001-15282 (opens in a new tab)PepBankPUB-11440277
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In diabetic patients with proliferative retinopathy, octreotide reduced vitreous hemorrhage incidence versus controls after 3 years (log rank p = 0.002).

    In plain wordsIn diabetic patients with proliferative retinopathy, octreotide reduced vitreous bleeding compared with untreated controls after 3 years.

    Peptide
    Octreotide
    Outcome
    DecreaseVitreous hemorrhage incidence
    Study

    n = 18

    Comparator
    Untreated diabetic controls
    Outcome group
    Vision and retina · Eye
    Studied dose
    100 microg tid · subcutaneous · maximum of 36 monthsAs given in this study (human).

    Source sentences

    Summary
    After 3 years of treatment, the incidence of vitreous hemorrhages and the need for vitreoretinal surgery was significantly lower (log rank test p = 0.002) in the octreotide-treated patients.
    3 context sentences
    Summary · context
    Randomized trial in a University hospital setting.
    Summary · context
    Nine patients received 100 microg tid octreotide (verum) subcutaneously for a maximum of 36 months.
    Summary · context
    Nine diabetics served as controls, no placebo treatment was used.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In diabetic patients with proliferative retinopathy, octreotide reduced the need for vitreoretinal surgery versus controls after 3 years (log rank p = 0.002).

    In plain wordsIn diabetic patients with proliferative retinopathy, octreotide reduced eye surgery requirements compared with untreated controls after 3 years.

    Peptide
    Octreotide
    Outcome
    DecreaseVitreoretinal surgery requirement
    Study

    n = 18

    Comparator
    Untreated diabetic controls
    Outcome group
    Vision and retina · Eye
    Studied dose
    100 microg tid · subcutaneous · maximum of 36 monthsAs given in this study (human).

    Source sentences

    Summary
    After 3 years of treatment, the incidence of vitreous hemorrhages and the need for vitreoretinal surgery was significantly lower (log rank test p = 0.002) in the octreotide-treated patients.
    3 context sentences
    Summary · context
    Randomized trial in a University hospital setting.
    Summary · context
    Nine patients received 100 microg tid octreotide (verum) subcutaneously for a maximum of 36 months.
    Summary · context
    Nine diabetics served as controls, no placebo treatment was used.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In diabetic patients with proliferative retinopathy, visual acuity was preserved and significantly better with octreotide than controls (p = 0.05).

    In plain wordsIn diabetic patients with proliferative retinopathy, octreotide preserved vision, which was better than in untreated controls.

    Peptide
    Octreotide
    Outcome
    Direction not reportedVisual acuity
    Study

    n = 18

    Comparator
    Untreated diabetic controls
    Outcome group
    Vision and retina · Eye
    Studied dose
    100 microg tid · subcutaneous · maximum of 36 monthsAs given in this study (human).

    Source sentences

    Summary
    Visual acuity was preserved and significantly better in the octreotide treated group compared to controls (p = 0.05).
    3 context sentences
    Summary · context
    Randomized trial in a University hospital setting.
    Summary · context
    Nine patients received 100 microg tid octreotide (verum) subcutaneously for a maximum of 36 months.
    Summary · context
    Nine diabetics served as controls, no placebo treatment was used.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.